investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Characterization and targeting BRIT1 deficiency in breast cancer
Kaiyi Li
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Kaiyi Li
Baylor College of Medicine
Houston, United States
Related projects
Raymond B Birge
Non-canonical signal pathway for Crk in breast cancer
Breast
Antony Gakwaya
What are the Possible Genetic Risk Factors of Breast Cancer in Black African Women?
Breast
Kuo-Hsiung Lee
Novel Antitumor Agents
Breast
Hugh S. Gannon
Extraordinary responder cell lines reveal unique targetable genetic dependencies
Breast
Thomas Sayers
Promoting Tumor Cell Apoptosis by Death Ligands
Breast
Ramesh K Ganju
Role of S100A7 in Breast Cancer Progression and Metastasis
Breast
Christopher H Contag
Dynamic Imaging of EMT in the Breast Cancer Microenvironment
Breast
Claudia Fischbach
Breast Microcalcifications and their Role in Breast Cancer Bone Metastasis
Breast
Fraser Symmans
Development of A Predictive Genomic Diagnostic Test for Survival Benefit from Everolimus (mTOR Inhibitor) Combined with Endocrine Therapy for Metastatic HR+/HER- Breast Cancer
Breast